SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-23-000011
Filing Date
2023-01-18
Accepted
2023-01-18 16:48:52
Documents
12
Period of Report
2023-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20230113.htm   iXBRL 8-K 36814
  Complete submission text file 0001479290-23-000011.txt   174283

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20230113.xsd EX-101.SCH 1937
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20230113_lab.xml EX-101.LAB 24137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20230113_pre.xml EX-101.PRE 12542
6 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20230113_htm.xml XML 11424
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 23534938
SIC: 2834 Pharmaceutical Preparations